Related Experiment Video

Updated: Aug 9, 2026

Examination of Thymic Positive and Negative Selection by Flow Cytometry
14:29

Examination of Thymic Positive and Negative Selection by Flow Cytometry

Published on: October 8, 2012

[bcl-2 expression in small cell lung cancer: a mechanism for apoptosis antagonism and immune evasion]

Jun-meng Zheng1, De-kun Wang, Hai-ming Jiang

  • 1Department of Cardiothoracic Surgery, People's Hospital of Zhongshan, Zhongshan 528403, China.

Di 1 Jun Yi Da Xue Xue Bao = Academic Journal of the First Medical College of PLA
|December 20, 2005
PubMed
Abstract

Insights

Small cell lung cancer cells use bcl-2 to evade immune attack. Bcl-2 antisense thio-oligonucleotide (bcl-2 SON) therapy shows promise by increasing cancer cell apoptosis when exposed to tumor-infiltrating lymphocytes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Context:

  • Small cell lung cancer (SCLC) is an aggressive malignancy.
  • The bcl-2 protein is implicated in cancer cell survival and resistance to apoptosis.
  • Understanding immune evasion mechanisms in SCLC is crucial for developing effective therapies.

Purpose:

  • To investigate the role of bcl-2 expression in SCLC immune evasion.
  • To evaluate the efficacy of bcl-2 antisense thio-oligonucleotide (bcl-2 SON) in sensitizing SCLC cells to immune attack.
  • To explore bcl-2 SON as a potential gene therapy for lung cancer.

Summary:

  • Western blotting confirmed that bcl-2 SON effectively inhibited bcl-2 expression in NCI-H69 SCLC cells.
  • Co-culture experiments with tumor-infiltrating lymphocytes (TILs) demonstrated increased apoptosis in bcl-2 SON-treated NCI-H69 cells and bcl-2-negative NCI-H82 cells.
  • Apoptosis induction correlated with the TIL ratio, while untreated NCI-H69 cells showed no significant change.

Impact:

  • Bcl-2 expression in SCLC may contribute to antagonizing anti-tumor immune responses.
  • Bcl-2 SON represents a potential therapeutic strategy for SCLC gene therapy.
  • This study provides a basis for developing novel immunotherapies targeting bcl-2 in lung cancer.

More Related Videos

Examining BCL-2 Family Function with Large Unilamellar Vesicles08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling08:51

Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling

Published on: June 25, 2015

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...